Randomised Evaluation of COVID-19 Therapy

NCT04381936 · clinicaltrials.gov ↗

PHASE3

Phase

RECRUITING

Status

70000

Enrollment

OTHER

Sponsor class

Conditions

Pneumonia

Interventions

DRUG: Lopinavir-Ritonavir
DRUG: Corticosteroid
DRUG: Hydroxychloroquine
DRUG: Azithromycin
BIOLOGICAL: Convalescent plasma
DRUG: Tocilizumab
BIOLOGICAL: Immunoglobulin
DRUG: Synthetic neutralising antibodies
DRUG: Aspirin
DRUG: Colchicine
DRUG: Baricitinib
DRUG: Anakinra
DRUG: Dimethyl fumarate
DRUG: High Dose Corticosteroid
DRUG: Empagliflozin
DRUG: Sotrovimab
DRUG: Molnupiravir
DRUG: Paxlovid
DRUG: Baloxavir Marboxil
DRUG: Oseltamivir

Sponsor

University of Oxford

Collaborators

[object Object]
[object Object]
[object Object]
[object Object]
[object Object]
[object Object]
[object Object]
[object Object]
[object Object]